

Please type a plus sign (+) inside this box → ☐

03-28-01

PTO/SB/05 (09-00)

Approved for use through 10/31/2002. OMB 0951-0032  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	LEX-0152-USA
First Inventor	D. Wade Walke et al.
Title	Novel Human Proteins and Polynucleotides Encoding the Same
Express Mail label No.	EL 826373148 US

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

- 1 ☐ Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for processing)
- 2 ☒ Applicant claims small entity status.  
See 37 CFR 1.27.
- 3 ☒ Specification [Total] Pages   
(preferred arrangement set forth below)
- Descriptive title of the invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the invention
  - Brief Summary of the invention
  - Brief Description of the drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the disclosure
- 4 ☐ Drawing(s) (35 U.S.C. 113) [Total]   
5. Oath or Declaration [Total]   
Pages
- a ☒ Unexecuted (original or copy)
- b ☐ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 17 completed)
- i ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s)  
named in the prior application, see 37 CFR  
1.63(d)(2) and 1.33(b)
- 6 ☐ Application Data Sheet See 37 CFR 1.76

**ADDRESS TO:**Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

- 7 ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
- 8 Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)

- a. ☐ Computer Readable Form (CRF)
- b. Specification Sequence Listing on:  
i ☐ CD-ROM or CD-R (2 copies); or  
ii ☒ paper
- c. ☐ Statements verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

- 9 ☐ Assignment Papers (cover sheet & document(s))
- 10 ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☒ Power of Attorney
- 11 ☐ English Translation Document (if applicable) ☐ Copies of IDS Citations
- 12 ☐ Information Disclosure Statement (IDS)/PTO-1449
- 13 ☐ Preliminary Amendment
- 14 ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
- 15 ☐ Certified Copy of Priority Documents(s)  
(if foreign priority is claimed)
- 16 ☒ Other: Request & Certification

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. \_\_\_\_\_  
Prior application information. Examiner: \_\_\_\_\_ Group/Art Unit: \_\_\_\_\_  
For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

**18. CORRESPONDENCE ADDRESS**☒ Customer Number or Bar Code Labelor ☐ Correspondence address below

Name	24231			
Address	PATENT, TRADEMARK OFFICE			
City	State	Zip		
Country	Telephone	Fax		

Name (Print/Type)	Lance K. Ishimoto	Registration No. (Attorney/Agent)	41855
Signature		Date	March 27, 2001

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

J1054 U.S. PTO  
03/27/01

030153000 03030000


J1002 U.S. PTO  
03/27/01

<b>REQUEST AND CERTIFICATION UNDER 35 U.S.C. 122(b)(2)(B)(i)</b>		First Named Inventor		D. Wade Walke et al.	
		Title		Novel Human Proteins and Polynucleotides Encoding the Same	
		Atty Docket Number		LEX-0152-USA	

31002 U.S. PTO  
 09/08/90  
 03/27/01

I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

March 27, 2001  
Date

  
 \_\_\_\_\_  
 Signature

\_\_\_\_\_  
 Lance K. Ishimoto  
 Typed or printed name

**This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application upon filing.**

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**